Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:MCRBNASDAQ:NGNENASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.49-8.1%$1.93$1.29▼$7.85$273.19M1.261.49 million shs1.05 million shsMCRBSeres Therapeutics$7.50-6.1%$8.43$6.53▼$30.60$65.49M2.62135,611 shs36,986 shsNGNENeurogene$19.76-3.1%$15.84$6.88▼$74.49$281.82M1.57250,566 shs112,718 shsPRTAProthena$5.08+0.2%$7.50$4.32▼$25.42$273.44M-0.08717,587 shs806,357 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%-4.23%+23.88%-9.45%-55.69%MCRBSeres Therapeutics0.00%-8.87%+0.54%-49.18%-47.06%NGNENeurogene0.00%-9.48%+9.84%+17.13%-53.60%PRTAProthena0.00%-6.10%-29.25%-63.03%-75.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.2187 of 5 stars3.52.00.00.02.90.80.6MCRBSeres Therapeutics3.5888 of 5 stars2.93.00.04.62.70.80.0NGNENeurogene3.4525 of 5 stars4.43.00.00.02.02.50.6PRTAProthena3.8777 of 5 stars4.24.00.00.03.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$12.50402.01% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67882.22% UpsideNGNENeurogene 2.71Moderate Buy$45.40129.76% UpsidePRTAProthena 2.33Hold$31.50520.08% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, ANNX, NGNE, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$22.00 ➝ $26.005/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/20/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.005/16/2025NGNENeurogeneBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AMCRBSeres Therapeutics$126.33M0.52N/AN/A($0.35) per share-21.43NGNENeurogene$925K304.67N/AN/A$14.51 per share1.36PRTAProthena$137.94M1.98N/AN/A$10.46 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.18N/AN/AN/AN/A-38.99%-33.90%8/11/2025 (Estimated)MCRBSeres Therapeutics-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%8/12/2025 (Estimated)NGNENeurogene-$36.32M-$4.35N/AN/AN/AN/A-32.81%-27.96%8/8/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/6/2025 (Estimated)Latest MCRB, ANNX, NGNE, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18MCRBSeres TherapeuticsN/A1.121.12NGNENeurogeneN/A9.099.09PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AMCRBSeres Therapeutics59.34%NGNENeurogene52.37%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%MCRBSeres Therapeutics4.70%NGNENeurogene11.64%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableMCRBSeres Therapeutics3308.73 million162.03 millionOptionableNGNENeurogene9014.26 million13.38 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableMCRB, ANNX, NGNE, and PRTA HeadlinesRecent News About These CompaniesProthena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16 at 2:27 AM | uk.finance.yahoo.comProthena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJune 16 at 1:06 AM | businesswire.comProthena Co. plc (NASDAQ:PRTA) Short Interest Down 50.7% in MayJune 14 at 12:05 PM | marketbeat.comCantor Fitzgerald Forecasts Prothena FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on Prothena FY2026 EarningsJune 10, 2025 | marketbeat.comPRTA Prothena Corporation plcJune 7, 2025 | seekingalpha.comShort Interest in Prothena Co. plc (NASDAQ:PRTA) Rises By 20.1%June 6, 2025 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Short Interest Up 20.1% in MayJune 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Prothena Co. plc (NASDAQ:PRTA)June 3, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by BrokeragesJune 1, 2025 | marketbeat.comFY2025 EPS Estimates for Prothena Cut by Chardan CapitalMay 31, 2025 | marketbeat.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comFY2027 EPS Estimates for Prothena Decreased by HC WainwrightMay 30, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)May 30, 2025 | marketbeat.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comProthena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of AmericaMay 29, 2025 | marketbeat.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 29, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMCRB, ANNX, NGNE, and PRTA Company DescriptionsAnnexon NASDAQ:ANNX$2.49 -0.22 (-8.12%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.64 +0.16 (+6.22%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Seres Therapeutics NASDAQ:MCRB$7.50 -0.49 (-6.13%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.84 +0.35 (+4.60%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Neurogene NASDAQ:NGNE$19.76 -0.64 (-3.14%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$19.77 +0.01 (+0.08%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Prothena NASDAQ:PRTA$5.08 +0.01 (+0.20%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.64 +0.56 (+11.00%) As of 06:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
